{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:27:16Z","timestamp":1774578436313,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T00:00:00Z","timestamp":1180051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    Perioral dermatitis (POD) is a common skin disease and difficult to treat. Pimecrolimus cream (1%) successfully controls atopic eczema.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    Our aim was to investigate its efficacy in POD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Study design\u2002<\/jats:bold>\n                    Single\u2010centre, randomized, double\u2010blind, vehicle\u2010controlled study including 40 POD patients with a 4\u2010week treatment and a 4\u2010week follow\u2010up. Efficacy was assessed by a novel Perioral Dermatitis Severity Index (PODSI) and Finlay's Dermatology Life Quality Index (DLQI).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting\u2002<\/jats:bold>\n                    Outpatient clinics of a large dermatological hospital in Munich, Germany.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    During treatment, the PODSI was significantly lower in the pimecrolimus group compared with vehicle (\n                    <jats:italic>P\u00a0=<\/jats:italic>\n                    \u00a00.005\u20130.02) whereas at follow\u2010up, no significant differences were observed. At week 2, the responder rates (\u2265\u00a050% PODSI improvement) were 50% with pimecrolimus cream (1%) and 25% with vehicle (\n                    <jats:italic>P\u00a0=<\/jats:italic>\n                    \u00a00.095). DLQI was improved in pimecrolimus group compared with vehicle.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                    Results suggest that pimecrolimus cream (1%) effectively treats acute\u2010stage POD.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2007.02191.x","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T07:26:27Z","timestamp":1180077987000},"page":"1175-1180","source":"Crossref","is-referenced-by-count":39,"title":["Pimecrolimus cream (1%) efficacy in perioral dermatitis \u2013 results of a randomized, double\u2010blind, vehicle\u2010controlled study in 40 patients"],"prefix":"10.1111","volume":"21","author":[{"given":"T","family":"Oppel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Pavicic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kamann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Br\u00e4utigam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,9,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01852.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1964.01590300031010"},{"key":"e_1_2_6_4_2","first-page":"475","article-title":"Perioral dermatitis","volume":"40","author":"Fritsch P","year":"1989","journal-title":"Hautarzt"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.5.3.643"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.117525"},{"issue":"3","key":"e_1_2_6_7_2","first-page":"356","article-title":"Irritative dermatitis of face and neck \u2013 therapy with pimecrolimus creme 1%","volume":"17","author":"Mensing CH","year":"2003","journal-title":"J Eur Acad Derm Venereol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06208.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06404.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0044"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000084754"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639309084514"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1087-0024.2004.09113.x"},{"key":"e_1_2_6_15_2","first-page":"708","article-title":"Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases","volume":"3","author":"Bornh\u00f6vd EC","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_6_16_2","first-page":"253","article-title":"\u00dcber den Wert der Tetrazyklin\u2010Therapie bei der perioralen Dermatitis","volume":"24","author":"Schubert E","year":"1973","journal-title":"Hautarzt"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70038-4"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.4.457"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112942"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.03.021"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.02.011"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2007.02191.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2007.02191.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:07:57Z","timestamp":1696943277000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2007.02191.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,14]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1468-3083.2007.02191.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02191.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1099367.555610","asserted-by":"object"}]},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,14]]}}}